<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Characteristics of peripheral neuropathy associated with cytotoxic chemotherapy agents</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Characteristics of peripheral neuropathy associated with cytotoxic chemotherapy agents</h1>
<div class="graphic"><div class="figure"><div class="ttl">Characteristics of peripheral neuropathy associated with cytotoxic chemotherapy agents</div><div class="cntnt"><table cellspacing="0"><colgroup span="6" width="16%"></colgroup> <tbody> <tr> <td class="subtitle1 divider_bottom" rowspan="2">Drug</td> <td class="subtitle1" colspan="4">Clinical manifestations</td> <td class="subtitle1 divider_bottom" rowspan="2">Recovery</td> </tr> <tr class="divider_bottom"> <td class="subtitle2">Sensory</td> <td class="subtitle2">Motor</td> <td class="subtitle2">Reflexes</td> <td class="subtitle2">Autonomic</td> </tr> <tr> <td colspan="6"><strong>Platinum compounds</strong></td> </tr> <tr> <td class="indent1">Cisplatin</td> <td>Distal, symmetric loss of sensation to all modalities, stocking glove distribution; painful paresthesias or numbness</td> <td>Normal</td> <td>In proportion to sensory loss</td> <td>Rare</td> <td>Partial; may progress for several months after drug is discontinued</td> </tr> <tr class="divider_bottom"> <td class="indent1">Carboplatin</td> <td>Similar but less severe than with cisplatin</td> <td>Normal</td> <td>Usually normal</td> <td>Rare</td> <td>Similar to cisplatin</td> </tr> <tr> <td colspan="6"><strong>Oxaliplatin</strong></td> </tr> <tr> <td class="indent1">Acute</td> <td>Cold-induced dysesthesias in mouth, throat, and upper limbs</td> <td>Cramps and/or muscle spasm in throat muscles</td> <td>Usually normal</td> <td>None</td> <td>Gets better within one week, but persists between two-week cycles; improves after chemotherapy is completed</td> </tr> <tr class="divider_bottom"> <td class="indent1">Chronic</td> <td>Similar to cisplatin; symptoms worse in upper extremities during active therapy, but upper extremity neuropathy improves faster than lower extremity neuropathy after treatment completion. One year after treatment completion, there is more neuropathy in lower extremities.</td> <td>Normal</td> <td>Usually normal</td> <td>Rare</td> <td>Generally starts to improve approximately three months after completion of chemotherapy; can be a chronic problem for some patients.</td> </tr> <tr> <td colspan="6"><strong>Vinca alkaloids</strong></td> </tr> <tr> <td class="indent1">Vincristine</td> <td class="divider_bottom" rowspan="4">Distal sensory loss lower extremities, rarely affects upper extremities; vinblastine and vinorelbine are less neurotoxic; vincristine - rare mononeuropathies</td> <td class="divider_bottom" rowspan="4">Less common; distal symmetric weakness in lower limbs progressing to foot drop</td> <td class="divider_bottom" rowspan="4">Early decrease or absent</td> <td class="divider_bottom" rowspan="4">Constipation common (especially vincristine), orthostatic hypotension less common</td> <td class="divider_bottom" rowspan="4">Usually resolves within three months; may persist with vincristine</td> </tr> <tr> <td class="indent1">Vinblastine</td> </tr> <tr> <td class="indent1">Vinorelbine</td> </tr> <tr class="divider_bottom"> <td class="indent1">Vindesine</td> </tr> <tr> <td colspan="6"><strong>Taxanes</strong></td> </tr> <tr> <td class="indent1">Paclitaxel</td> <td class="divider_bottom" rowspan="2">Mild distal loss of sensation to all modalities, feet greater than hands, painful paresthesias</td> <td class="divider_bottom" rowspan="2">Occasional mild weakness in foot muscles; myalgia, myopathy</td> <td class="divider_bottom" rowspan="2">Reduced ankle reflexes</td> <td class="divider_bottom" rowspan="2">Rare</td> <td class="divider_bottom" rowspan="2">Usually improves after treatment, but persistent symptoms in about 50% of patients one year later</td> </tr> <tr class="divider_bottom"> <td class="indent1">Docetaxel</td> </tr> <tr class="divider_bottom"> <td><strong>Bortezomib</strong></td> <td>Mild to moderate distal symmetric loss of sensation to all modalities in distal extremities; painful paresthesias</td> <td>Occasional mild distal weakness in lower limbs; rare severe distal weakness; muscle cramps and fasciculations rare</td> <td>In proportion to sensory loss</td> <td>Occasional, including orthostatic hypotension, diarrhea, and constipation</td> <td>Usually resolves within three months; may persist</td> </tr> <tr class="divider_bottom"> <td><strong>Ixabepilone</strong></td> <td>Painful paresthesias; distal loss of sensation</td> <td>10 to 16% have weakness</td> <td>Rare</td> <td>Rare</td> <td>Usually improves after stopping</td> </tr> <tr> <td class="divider_bottom"><strong>Thalidomide</strong></td> <td rowspan="3">Symmetric mild to moderate distal loss to all sensory modalities</td> <td rowspan="3">Weakness and tremor in 30 to 40%; muscle cramps and fasciculations common</td> <td rowspan="3">In proportion to sensory loss</td> <td rowspan="3">Constipation; other manifestations (impotence, bradycardia) are rare</td> <td rowspan="3">Partially reversible; may persist for over one year</td> </tr> <tr class="divider_bottom"> <td><strong>Lenalidomide</strong></td> </tr> <tr> <td><strong>Pomalidomide</strong></td> </tr> </tbody></table></div><div id="graphicVersion">Graphic 67516 Version 9.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
